[H17] HRP-conjugated Goat Anti-CBL (Carbamyl-lysine)CBL30H-G1a
|Concentration:||1 mg/ml (OD 1.35 / 280 nm)|
|Buffer:||50 mM PBS, 0.1 M NaCl, and 0.01% Thiomersal, pH 7.4.|
Specifically binds to CBL modified proteins. Dilution for immunoblot and ELISA range: 1,000 to 4,000.
The antibody can be used for detection of CRP in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
|Storage:||-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.|
|Form:||Freeze dried powder|
|Stabilizer:||10 mg / ml Bovine Serum Albumin.|
Freeze-dried product should be stored refrigerated until opened. After opening, restore to suggested ml volume with distilled water. If it is not completely clear after standing for 1-2 hours at room temperature, centrifuge the product. It is stable for several weeks at 4°C as an undiluted liquid. Do not use for more than one day after dilution. For extended storage after reconstitution, we suggest aliquot to avoid repeated freezing and thawing; or the addition of an equal volume of glycerol to make a final glycerol concentration of 50%, followed by storage at -20°C. The concentration of protein and buffer salts will decrease to one-half of the original after the addition of glycerol.
*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
Human C-Reactive Protein (CRP) is an important biomarker for predicting of future cardiovascular events, such as heart attack and stroke (Koenig et al., 1999, Jenny et al., 2007, Kabagambe et al. 2011). CRP is an acute phase protein produced by the liver. It is a member of the pentraxin family of proteins with five identical nonglycosylated subunits of 206 amino acids each (m.w. 23 kDa) (Agrawal et al., 2009). Among other markers of inflammation, CRP has shown the strongest association with cardiovascular events (Marsik et al., 2008, Kones et al., 2010). Clinical studies demonstrated that coronary mortality among patients with unstable angina and elevated CRP is significantly higher comparing with the patients without elevated CRP. It is an important biomarker for detecting individuals at high risk of plaque rapture.
Agrawal, Alok, Prem Prakash Singh, Barbara Bottazzi, Cecilia Garlanda, and Alberto Mantovani. "Pattern Recognition by Pentraxins." Advances in Experimental Medicine and Biology 653 (2009): 98-116.
Jenny, N. S., N. D. Yanez, B. M. Psaty, L. H. Kuller, C. H. Hirsch, and R. P. Tracy. "Inflammation Biomarkers and Near-Term Death in Older Men." American Journal of Epidemiology 165 (2007): 684-95.
Kabagambe, E. K., S. E. Judd, V. J. Howard, N. A. Zakai, N. S. Jenny, M. Hsieh, D. G. Warnock, and M. Cushman. "Inflammation Biomarkers and Risk of All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke Cohort." American Journal of Epidemiology 174 (2011): 284-92.
Koenig, W., M. Sund, M. Frohlich, H.-G. Fischer, H. Lowel, A. Doring, W. L. Hutchinson, and M. B. Pepys. "C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men: Results From the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 198." Circulation 99 (1999): 237-42.
Kones, Richard. "Rosuvastatin, Inflammation, C-reactive Protein, JUPITER, and Primary Prevention of Cardiovascular Disease – a Perspective." DDDT Drug Design, Development and Therapy 4 (2010): 383.
Marsik, C., L. Kazemi-Shirazi, T. Schickbauer, S. Winkler, C. Joukhadar, O. F. Wagner, and G. Endler. "C-Reactive Protein and All-Cause Mortality in a Large Hospital-Based Cohort." Clinical Chemistry 54 (2008): 343-49.